Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207699 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT02207699 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 68 participants.
The verdict
NCT02207699, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the effects of benzonatate (200 mg and 800 mg) on the QT interval following single dose oral administration at each time point post-dose.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin 400 mg
- DRUG Benzonatate 200 mg
- DRUG Benzonatate 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207699
The ClinicalTrials.gov registry entry for NCT02207699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02207699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207699 about?
NCT02207699 is a clinical study titled "Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers". The primary objective of this study is to determine the effects of benzonatate (200 mg and 800 mg) on the QT interval following single dose oral administration at each time point post-dose.
What is the current status of trial NCT02207699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02207699?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin 400 mg (DRUG), Benzonatate 200 mg (DRUG), Benzonatate 800 mg (DRUG).
Who is sponsoring clinical trial NCT02207699?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.